BACKGROUND: Raltegravir (RAL) plus tenofovir/emtricitabine (TDF/FTC) is a recommended initial antiretroviral regimen. A substantial proportion of persons diagnosed with HIV infection and starting antiretrovirals in the U.S. are African-American (AA); however, the effects of this regimen on metabolic parameters have largely been studied in white patients. METHODS: Single-arm, open-label study of untreated AA HIV-infected patients administered RAL with TDF/FTC for 104 weeks. Changes in fasting lipids, insulin resistance, visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT), limb and trunk fat, and bone mineral density (BMD) were assessed at weeks 56 and 104. RESULTS: Thirty (85% men) participants were included. Median entry characteristics included age of 38 years, CD4 323 cells/mm3, HIV RNA level 29,245 copies/ml, and body mass index 28.1 kg/m2. At 56 and 104 weeks, significant increases in VAT, trunk fat, limb fat, and overall fat were observed. Bone mineral density decreased by 1.5% by week 104.There were no significant changes in non-HDL-cholesterol, fasting triglycerides, or insulin resistance. A median CD4 cell count increase of 318 cells/mm3 (IQR 179, 403; full range 40, 749) (P<0.001) was observed. Assuming missing=failure, 78 and 70% had HIV RNA levels<40 copies/ml at weeks 56 and 104, respectively. There were no treatment-related discontinuations and no new antiretroviral resistance mutations were detected. CONCLUSIONS: In this cohort of AAs, initiation of RAL with TDF/FTC was associated with significant general increases in fat. Significant changes in lipids or insulin resistance were not observed and there was a small decline in BMD. Therapy was well tolerated and effective. These results are consistent with findings of studies of initial antiretroviral therapy in racially diverse cohorts and inform treatment selection for AA patients starting therapy for HIV infection.
BACKGROUND:Raltegravir (RAL) plus tenofovir/emtricitabine (TDF/FTC) is a recommended initial antiretroviral regimen. A substantial proportion of persons diagnosed with HIV infection and starting antiretrovirals in the U.S. are African-American (AA); however, the effects of this regimen on metabolic parameters have largely been studied in white patients. METHODS: Single-arm, open-label study of untreated AA HIV-infectedpatients administered RAL with TDF/FTC for 104 weeks. Changes in fasting lipids, insulin resistance, visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT), limb and trunk fat, and bone mineral density (BMD) were assessed at weeks 56 and 104. RESULTS: Thirty (85% men) participants were included. Median entry characteristics included age of 38 years, CD4 323 cells/mm3, HIV RNA level 29,245 copies/ml, and body mass index 28.1 kg/m2. At 56 and 104 weeks, significant increases in VAT, trunk fat, limb fat, and overall fat were observed. Bone mineral density decreased by 1.5% by week 104.There were no significant changes in non-HDL-cholesterol, fasting triglycerides, or insulin resistance. A median CD4 cell count increase of 318 cells/mm3 (IQR 179, 403; full range 40, 749) (P<0.001) was observed. Assuming missing=failure, 78 and 70% had HIV RNA levels<40 copies/ml at weeks 56 and 104, respectively. There were no treatment-related discontinuations and no new antiretroviral resistance mutations were detected. CONCLUSIONS: In this cohort of AAs, initiation of RAL with TDF/FTC was associated with significant general increases in fat. Significant changes in lipids or insulin resistance were not observed and there was a small decline in BMD. Therapy was well tolerated and effective. These results are consistent with findings of studies of initial antiretroviral therapy in racially diverse cohorts and inform treatment selection for AA patients starting therapy for HIV infection.
Entities:
Keywords:
African-American; Bone density,; Lipodystrophy,; Raltegravir,
Authors: Nisha Andany; Janet M Raboud; Sharon Walmsley; Christina Diong; Sean B Rourke; Sergio Rueda; Anita Rachlis; Wendy Wobeser; Rodger D Macarthur; Louise Binder; Ron Rosenes; Mona R Loutfy Journal: HIV Clin Trials Date: 2011 Mar-Apr
Authors: Adrian Curran; Esteban Martinez; Maria Saumoy; Luis del Rio; Manuel Crespo; Maria Larrousse; Daniel Podzamczer; Joaquin Burgos; Montse Lonca; Pere Domingo; Jose Maria Gatell; Esteban Ribera Journal: AIDS Date: 2012-02-20 Impact factor: 4.177
Authors: Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: David W Haas; Tebeb Gebretsadik; Gail Mayo; Usha N Menon; Edward P Acosta; Ayumi Shintani; Michael Floyd; C Michael Stein; Grant R Wilkinson Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: Matthew J Nicholaou; Jeremy J Martinson; Alison G Abraham; Todd T Brown; Shehnaz K Hussain; Steven M Wolinsky; Lawrence A Kingsley Journal: AIDS Res Hum Retroviruses Date: 2013-03-08 Impact factor: 2.205
Authors: Jeffrey L Lennox; Raphael J Landovitz; Heather J Ribaudo; Ighovwerha Ofotokun; Lumine H Na; Catherine Godfrey; Daniel R Kuritzkes; Manish Sagar; Todd T Brown; Susan E Cohn; Grace A McComsey; Francesca Aweeka; Carl J Fichtenbaum; Rachel M Presti; Susan L Koletar; David W Haas; Kristine B Patterson; Constance A Benson; Bryan P Baugh; Randi Y Leavitt; James F Rooney; Daniel Seekins; Judith S Currier Journal: Ann Intern Med Date: 2014-10-07 Impact factor: 25.391
Authors: David A Wohl; Julie B Dumond; Suzanne Blevins; Donna Pittard; David Ragan; Ruili Wang; Kelley Massengale; Kendall Walsh; Michelle Floris-Moore; Joseph J Eron; Amy Richardson; Michael G Hudgens; Angela D M Kashuba Journal: Antimicrob Agents Chemother Date: 2012-11-26 Impact factor: 5.191
Authors: Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.771
Authors: Sahera Dirajlal-Fargo; Carlee Moser; Todd T Brown; Theodoros Kelesidis; Michael P Dube; James H Stein; Judith Currier; Grace A McComsey Journal: Open Forum Infect Dis Date: 2016-08-29 Impact factor: 3.835
Authors: Dmitri Sviridov; Nigora Mukhamedova; Alexander A Makarov; Alexei Adzhubei; Michael Bukrinsky Journal: AIDS Date: 2020-01-01 Impact factor: 4.632